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Abstract Loss-of-function mutations in AGPAT2,
encoding 1-acylglycerol-3-phosphate-O-acyltransferase
2 (AGPAT2), produce congenital generalised lipodys-
trophy (CGL). We screened the AGPAT2 gene in two
siblings who presented with pseudoacromegaly, diabetes
and severe dyslipidaemia and identified a novel mutation
in AGPAT2 causing a single amino acid substitution,
p.Cys48Arg. We subsequently investigated the molecular
pathogenic mechanism linking both this mutation and the
previously reported p.Leu228Pro mutation to clinical
disease. Wild-type and mutant AGPAT2 were expressed
in control and AGPAT2-deficient preadipocyte cell lines.
mRNA and protein expression was determined, and the
ability of each AGPAT2 species to rescue adipocyte
differentiation in AGPAT2-deficient cells was assessed.
Protein levels of both p.Cys48Arg and p.Leu228Pro
AGPAT2 were significantly reduced compared with that
of wild-type AGPAT2 despite equivalent mRNA levels.
Stable expression of wild-type AGPAT2 partially rescued
adipogenesis in AGPAT2 deficient preadipocytes, whereas
stable expression of p.Cys48Arg or p.Leu228Pro AGPAT2
did not. In conclusion, unusually severe dyslipidaemia and
pseudoacromegaloid overgrowth in patients with diabetes
should alert physicians to the possibility of lipodystrophy.
Both the previously unreported pathogenic p.Cys48Arg
mutation in AGPAT2, and the known p.Leu228Pro
mutation result in decreased AGPAT2 protein expression
in developing adipocytes. It is most likely that the CGL
seen in homozygous carriers of these mutations is largely
accounted for by loss of protein expression.
Introduction
Congenital generalised lipodystrophy (CGL) is a rare
autosomal recessive disease characterised by nearly global
loss of adipose tissue from birth. Affected individuals are
commonly severely dyslipidaemic, insulin resistant, and
eventually diabetic and suffer a commensurately high rate
of microvascular and macrovascular complications, as well
as a high rate of severe fatty liver disease and pancreatitis.
Like many other patients with extreme forms of insulin
resistance, they may also exhibit acromegaloid soft tissue
overgrowth without any evidence of growth hormone or
IGF1 excess. Although the diagnosis of CGL is usually
made based on the observation of absent adipose tissue on
clinical examination, the severity of the complications and
collateral clinical and biochemical features may serve to
alert clinicians to the underlying diagnosis.
Defects in four genes – AGPAT2, BSCL2, CAV1, and
PTRF – have been implicated in CGL to date (OMIM:
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608594, 269700, 612526, and 613327, respectively)
(Rochford 2010). AGPAT2, the first of these to be reported,
was implicated first by genetic mapping of the disease locus
to chromosome 9q34, followed by identification of the
disrupted gene in 2002 (Agarwal et al. 2002). Patients with
AGPAT2 mutations fail to develop metabolically active
adipose tissue in most subcutaneous, intra-abdominal, intra-
thoracic, and bone marrow fat depots, as ascertained by
whole-body magnetic resonance imaging. However, they
often have preserved mechanical adipose tissue depots in
the palms, soles, scalp, retro-orbital, and peri-articular
regions (Agarwal et al. 2003).
AGPAT2 encodes a 278 amino acid acyltransferase,
1-acylglycerol-3-phosphate-O-acyltransferase 2 (AGPAT2)
that converts lysophosphatidic acid (LPA) to phosphatidic
acid (PA), a key step in the triacylglycerol (TG) biosynthesis
pathway (Shindou et al. 2009). AGPAT2 is highly expressed
in human adipose tissues, liver, pancreas, skeletal muscles,
and small intestine (Shindou et al. 2009). Most reported
AGPAT2 mutations in CGL cause frame-shifts, insertions,
deletions, or affect splicing, and are predicted to be
functionally null alleles. Only a small number of pathogenic
amino acid substitutions have been described to date (Hegele
et al. 2007; Huang-Doran et al. 2010; Pelosini et al. 2011). In
this report, we describe and characterise a novel missense
mutation in the poorly characterised amino terminal domain
of AGPAT2, p.Cys48Arg, identified in two female patients
with CGL.
Methods
Mutational Analysis
Genomic DNA was extracted from peripheral blood
leukocytes before PCR amplification of all coding exons
of the AGPAT2 and BSCL2 genes plus 50 bp of flanking
sequence at either end of the exons employing primers
designed using ExonPrimer via the USC genome browser
(http://genome.ucsc.edu/) and checked for common poly-
morphisms. The PCR products were purified using Agen-
court® CleanSEQ® reagents (Agencourt Bioscience,
Beverly, MA, USA) and sequenced in both directions using
the BigDye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, PerkinElmer, Foster City, CA, USA)
and an ABI 3730 DNA sequencer (Applied Biosystems).
Sequence analysis was performed using Sequencher soft-
ware (Gene Codes, Ann Arbor, MI).
Biochemical Assays
Insulin, leptin, and adiponectin were all assayed on a 1235
AutoDELFIA (PerkinElmer Lifesciences, Boston, MA) auto-
matic immunoassay system using two-step time-resolved
fluorometric assays as previously described (Semple et al.
2006). SHBG was determined using an IMMULITE 1,000
solid phase chemiluminescent enzyme immunometric assay
(Siemens Medical Solutions Diagnostics). Testosterone was
measured by a solid phase extraction RIA (Siemens Health-
care Diagnostics, Surrey, UK; formally DPC Coat-A-Count)
using protocols provided by the manufacturer. Triglyceride
concentrations were assayed in singleton on the Dimension
RXL system (Dade Behring, Milton Keynes, UK). Plasma
(total) IGF-I concentrations were measured in ethanolic
extracts using aDSLELISA (DSL-UK Ltd., Upper Heyford,
Oxon, UK) according to the manufacturer’s instructions.
Cell Culture
C3H10T1/2 murine mesenchymal stem cells and 3T3-L1
preadipocytes were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10 % newborn calf serum
(NCS) as previously described (Payne et al. 2008). shRNA
sequences targeting AGPAT2 were designed and cloned
into the RNAi-Ready pSIREN-RetroQ vector (Clontech)
and shRNA targeting luciferase used as a control. Wild-
type human AGPAT2 was cloned into pcDNA3.1myc-HisA
vector (Invitrogen) and p.Cys48Arg and p.Leu228Pro
mutant forms created by site directed mutagenesis. Myc-
tagged AGPAT2 constructs were subcloned into the pBabe
retroviral vector. Retroviruses carrying shRNA or cDNA
constructs were used to infect preadipocyte cell lines as
previously described (Payne et al. 2008). Oil Red O
staining of lipid accumulation was as described in (Payne
et al. 2008).
Western Blot Analysis
Cells were scraped in lysis buffer (50mMTris pH6.8, 150mM
NaCl, 1mM EDTA, Complete Protease Inhibitor Cocktail
(Roche), PhosSTOP Phosphatase Inhibitor Cocktail (Roche),
and 50mMn-b-D-glucopyranoside (Calbiochem)), sonicated,
centrifuged at 14,000g for 10 min and protein concentration
determined using a (BCA) kit (Bio-Rad). Samples containing
equal amounts of protein were resolved on a NuPAGE®
Novex® 4–12 % Bis-Tris precast gels (Invitrogen) and
transferred using iBlot® (Invitrogen). Membranes were
blocked in 5 % milk then probed with anti-myc (mouse
monoclonal 4A6) (Milipore) or anti-calnexin antibodies.
Secondary antibodies were from Thermo Scientific and
signals were detected using ECL (GE Healthcare).
Real Time PCR
Cells were collected and RNA isolated using an RNAeasy
kit (Qiagen). Purified RNA was reverse transcribed using
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random hexamers and M-MLV reverse transcriptase
(Promega). Gene expression was assayed by qPCR using
either TaqMan® primers and probes (ABI Biosystems) or
SYBR green and normalised to cyclophilin A.
Case Histories
This study was conducted in accordance with the Declara-
tion of Helsinki and approved by the UK national research
ethics committee. Written informed consent was obtained
from both participants.
Patient A (14 years old at presentation) and her sister
patient B (17 years old), both from Saudi Arabia, presented
complaining of a male habitus and oligomenorrhoea. Their
parents were first cousins (Fig. 1a). Both sisters were lean
with marked hirsutism, androgenetic alopecia, deep voices,
and muscle hypertrophy. They also had acanthosis nigricans
with acrochordons (Fig. 1b), a markedly acromegaloid
facial appearance (Fig. 1b), relatively large hands and feet,
and although a paucity of subcutaneous fat was also noted,
it was these features of overgrowth that were the focus of
the initial diagnostic evaluation. Both patients had severe
Fig. 1 (a) Family pedigree of the lipodystrophic patients in this study.
Patients A and B are homozygous for the AGPAT2 p.Cys48Arg
mutation, while family members in red are heterozygotes.
(b) Appearance of patient A, showing acromegaloid overgrowth
(upper left image) and acanthosis nigricans of the foot (upper right
image) and nuchal acanthosis nigricans (lower image). (c) Biochemi-
cal profile of the patients studied
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hyperinsulinemia, hypertriglyceridemia, and hyperandroge-
nemia with low sex hormone binding globulin (Fig. 1c).
Serum IGF-1 and growth hormone response to 75 g oral
glucose, and 17 hydroxyprogesterone response to 250 mcg
synthetic ACTH were normal. At 15 years old patient A
was found to be diabetic with an HbAIC of 16.4 %, and
metformin, glyburide, gemfibrozil, and simvastatin were
commenced. Subsequently insulin was introduced and
titrated to 166 units/day, along with a maximal dose of
pioglitazone. Despite these measures proliferative retinopathy,
nephropathy, neuropathy, and severe hepatic steatosis
developed. At that stage serum adiponectin and leptin were
nearly undetectable, in keeping with near complete absence
of adipose tissue. Patient B developed diabetes at 18 years
old and is currently taking metformin and pioglitazone with
no complications to date.
Results
No rare sequence variants were identified in the BSCL2
gene; however, both affected probands were found to be
homozygous for the AGPAT2 c.142T>C transversion,
producing the p.Cys48Arg missense change in the AGPAT2
protein (representative chromatogram Fig. 2a lower panel).
Both parents, and two clinically unaffected siblings
available for testing were heterozygous for the mutation
(representative chromatogram Fig. 2a middle panel), which
Fig. 2 (a) Representative chromatograms from sequencing genomic
DNA of wild-type individuals (upper panel) or heterozygote (middle
panel) or homozygote (lower panel) carriers of the AGPAT2
p.Cys48Arg mutation. (b) Schematic diagram showing the location
of the acyltransferase domain and the p.Cys48Arg and p.Leu228Pro
mutations within AGPAT2. Transmembrane domains are shown in
grey. Phylogenic conservation of Cys48 and Leu228 are shown below
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was absent from more than 900 control patients from a
panel of different ethnicities. In addition, the variant was
not found in the NHLBI ESP Exome Variant Server,
including around 4,000 people drawn from various cohort
studies (NHLBI Exome Sequencing Project Exome Variant
Browser (ESP), Seattle, WA, URL: http://evs.gs.washing-
ton.edu/EVS/) accessed October 2011). Cysteine 48 is
highly phylogenetically conserved (Fig. 2b) and falls within
the second transmembrane domain of AGPAT2.
To assess the effect of the AGPAT2 p.Cys48Arg
mutation we generated 3T3-L1 murine preadipocytes stably
expressing wild-type human AGPAT2, AGPAT2 Cys48Arg,
or the previously described AGPAT2 Leu228Pro. The latter
was selected as Leu228 is the most phylogenetically
conserved of the residues reported to be substituted in
CGL, being invariant in all species examined (Fig. 2b).
This suggests that it may serve a particularly critical
function in the mature AGPAT2 enzyme. Consistent with
this AGPAT2 Leu228Pro has the lowest activity of any
pathogenic single amino acid substitutions in AGPAT2
examined in a previous study (Haque et al. 2005). Western
blotting revealed dramatically lower expression of the
Leu228Pro and Cys48Arg mutant proteins compared to
wild-type AGPAT2 in confluent preadipocytes (Fig. 3a). To
investigate this further human AGPAT2 mRNA was
determined using a quantitative real time PCR assay that
did not detect murine AGPAT2 mRNA. As expected, no
human AGPAT2 mRNA expression was detected in control
cells whilst equal levels were present in cells expressing
AGPAT2 wild-type, Leu228Pro, or Cys48Arg (Fig. 3b).
The low expression of mutant AGPAT2 protein with normal
mRNA levels suggests that both Leu228Pro and Cys48Arg
AGPAT2 mutations most likely affect AGPAT2 folding
and/or stability.
In order to model the in vivo situation in lipodystrophic
patients more faithfully the effect of expressing wild-type
or mutant AGPAT2 in murine preadipocytes with stable
Agpat2 knockdown was examined. Murine Agpat2 was
selectively knocked down in the C3H10T1/2 mesenchymal
stem cell line using retroviruses expressing either control
shRNA or mouse-specific shRNA against Agpat2. As
shown in Fig. 3c, the low levels of Agpat2 present in
undifferentiated cells were significantly reduced by expres-
sion of shRNA targeting murine Agpat2. When Agpat2
knockdown cells were induced to differentiate for 8 days in
culture they showed significantly impaired expression of
the key adipogenic transcription factor PPARg and the
insulin-sensitive glucose transporter Glut4, both well-
characterised markers of adipogenesis (Fig. 3d). Human
wild-type Leu228Pro or Cys48Arg AGPAT2 were then
overexpressed stably using a second retroviral vector. As in
3T3-L1 cells, expression of Leu228Pro and Cys48Arg
AGPAT2 proteins was significantly reduced compared to
wild-type (Fig. 3e). This was despite equivalent expression
of wild-type or mutant AGPAT2 mRNAs both as confluent
preadipocytes and at various time points following induction
of differentiation in these cells (Fig. 3f). Moreover the
Leu228Pro and Cys48Arg AGPAT2 proteins remained
undetectable at various time points tested following adipo-
genic induction (Fig. 3g). Consistent with this, expression of
wild-type AGPAT2 partially rescued adipogenesis in
AGPAT2 knockdown cells whereas neither Leu228Pro nor
Cys48Arg mutant AGPAT2 constructs were able to do so
when assessed by either light microscopy or oil red O
staining of lipid accumulation (Fig. 3h) or by assessment of
the induction of Pparg mRNA expression (Fig. 3i).
Discussion
CGL is usually recognised in infancy due to severe lack of
adipose tissue. However, these cases are a reminder that in
older patients collateral features of lack of adipose tissue,
including severe dyslipidaemia and fatty liver disease, and
the hyperandrogenic and pseudoacromegalic features of
severe insulin resistance, may instead dominate the
clinical presentation. Thus, each of these should serve as
‘red flags’ alerting physicians to possible underlying
lipodystrophy.
We investigated the effect of a novel pathogenic mutation
in AGPAT2, p.Cys48Arg, and a previously described
mutation, p.Leu228Pro, on the function of AGPAT2. Both
mutations led to dramatically reduced protein expression
suggesting that this may be the dominant reason for failure
of adipose tissue formation in these patients. As the mutant
forms of AGPAT2 were very poorly expressed it would not
be trivial to assess their enzymatic activity accurately. As
such we cannot formally exclude the possibility that, should
these proteins be expressed in the affected individuals, they
might also display reduced enzymatic activity. Whilst it may
seem surprising that a single amino acid substitution so
dramatically affects protein expression this has been
observed with pathogenic mutations in other proteins such
as steroid 5b-reductase (Mindnich et al. 2011). As the p.
Cys48Arg mutation occurs in the putative second transmem-
brane domain of AGPAT2 it is possible that the mutation
causes misfolding of this domain and altered membrane
insertion, leading to degradation. However, a fuller under-
standing of the structure of AGAPT2 and further studies
including modelling of this mutation would be required to
determine this. A previous study of several pathogenic
mutations in AGPAT2 including p.Leu228Pro (Haque et al.
2005) reported that Leu228Pro AGPAT2 exhibited signifi-
cantly lower AGPAT activity than wild-type AGPAT2.
However, critically, the expression of wild-type AGPAT2
was not directly assessed in parallel. Given our findings that
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Fig. 3 (a) Protein levels of myc-tagged AGPAT2 determined by
immunoblotting in 3T3-L1 preadipocytes stably expressing wild-type
(WT) Leu228Pro (L228P) or Cys48Arg (C48R) AGPAT2 compared to
mock infected cells. Data shown are mean +/ SEM of three
independent experiments normalised to calnexin expression in the same
samples as a loading control, * indicates a difference of p < 0.05
compared with expression of the wild-type AGPAT2. A representative
blot is shown above. (b) AGPAT2 mRNA levels in the same cells as (A)
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both p.Leu228Pro and p.Cys48Arg are expressed at signifi-
cantly reduced levels, it will be interesting to determine
whether this may also be so with other pathogenic mutants of
AGPAT2 found in CGL patients.
The precise mechanism whereby AGPAT2 affects
the complex process of adipogenesis remains unclear.
However, it is evident that AGPAT2 deficiency does not
merely result in the selective loss of triglyceride synthesis.
Knockdown of AGPAT2 expression in cultured preadipo-
cytes results in marked inhibition of adipogenic gene
expression (Gale et al. 2006). The recent demonstration
that, as in humans, Agpat2 deficiency in mice produces
generalised lipodystrophy and severe insulin resistance
provides an in vivo model for further investigations (Cortes
et al. 2009). AGPAT2 loss may alter the generation of lipid
species that can directly or indirectly play a role in
modulating gene transcription. PA, the product of AGPAT2
activity, is a key intermediate in the production of several
phospholipids which may influence both biogenesis and/or
intracellular signalling. Interestingly, AGPAT2 inhibition in
vascular smooth muscle cells suppresses the activation of
PI3-kinase/AKT and MAPK pathways, both known to have
roles in adipocyte differentiation (Coon et al. 2003).
Evidently, further studies will be required to elucidate
which, if any of these pathways, may be influenced by
AGPAT2 during adipocyte development.
This study is the first to rescue adipogenesis in cultured
cells lacking AGPAT2 by transfection with the wild-type
enzyme and to demonstrate that expression of pathogenic
mutants of AGPAT2 cannot do this. In the case of the
mutants examined here this resulted from dramatically
reduced expression of the mutants. However, it demon-
strates that this system may be valuable for studying the
underlying pathogenic mechanism of other mutants where
protein expression is not affected.
In conclusion, we report the novel Cys48Arg pathogenic
mutation in AGPAT2 and show that this and the previously
described Leu228Pro mutation lead to dramatically reduced
protein expression. Whilst we cannot exclude the possibility
that Cys48Arg and Leu228Pro forms of AGPAT2 may also
exhibit reduced enzymatic activity, we suggest that reduced
expression of these mutated proteins may significantly
contribute to the CGL phenotype seen in these patients.
Summary
Loss-of-function mutations in AGPAT2, encoding
1-acylglycerol-3-phosphate-O-acyltransferase 2 (AGPAT2),
produce congenital generalised lipodystrophy (CGL). We
screened the AGPAT2 gene in two siblings who presented
with pseudoacromegaly, diabetes, and severe dyslipidaemia
and identified a novel mutation in AGPAT2 causing a single
amino acid substitution, p.Cys48Arg. We subsequently
investigated the molecular pathogenic mechanism linking
both this mutation and the previously reported p.Leu228Pro
mutation to clinical disease. Wild-type and mutant AGPAT2
were expressed in control and AGPAT2-deficient preadipo-
cyte cell lines. mRNA and protein expression were deter-
mined, and the ability of each AGPAT2 species to rescue
adipocyte differentiation in AGPAT2-deficient cells
was assessed. Protein levels of both p.Cys48Arg and
p.Leu228Pro AGPAT2 were significantly reduced compared
with that of wild-type AGPAT2 despite equivalent mRNA
levels. Stable expression of wild-type AGPAT2 partially
rescued adipogenesis in AGPAT2 deficient preadipocytes
whereas stable expression of p.Cys48Arg or p.Leu228Pro
AGPAT2 did not. In conclusion, unusually severe dyslipi-
daemia and pseudoacromegaloid overgrowth in patients
with diabetes should alert physicians to the possibility of
lipodystrophy. Both the previously unreported pathogenic
p.Cys48Arg mutation in AGPAT2, and the known p.
Leu228Pro mutation result in decreased AGPAT2 protein
expression in developing adipocytes. It is most likely that the
CGL seen in homozygous carriers of these mutations is
largely accounted for by loss of protein expression.
(C) AGPAT2 mRNA levels in murine C3H10 T1/2 cells with
(shAGPAT2) or without (Con) stable expression of shRNA targeting
murine AGPAT2. (d) Pparg2 and Glut4 mRNA levels after 8 days of
adipogenic differentiation in C3H10T1/2 cells stably expressing either
control shRNA (black bars) or murine AGPAT2 shRNA (white bars) (e)
Protein levels of AGPAT2 after stable expression of human wild-type or
mutant AGPAT2 in C3H10T1/2 cells with stable murine Agpat2
knockdown determined by immunoblotting. Data shown are mean
+/ SEM of 3 independent experiments normalised to calnexin
expression in the same samples as a loading control, * indicates a
difference of p < 0.05 compared with expression of the wild-type
AGPAT2. A representative blot is shown above. (f) human AGPAT2
mRNA levels in the cells in (E) following induction of adipogenesis for
the times shown. (g) Protein levels of myc-tagged wild-type and mutant
AGPAT2 in the same cells as in (f) during adipogenic differentiation,
assessed by immunoblotting, with calnexin as a loading control.
(h) Triglyceride accumulation assessed by light microscopy (upper
panels) and Oil Red O staining (lower panels) in C3H10T1/2 cells with
stable Agpat2 knockdown and human wild-type or mutant AGPAT2
re-expression after 8 days of adipogenic differentiation. (i) Real time
PCR analysis of Pparg mRNA expression in C3H10T1/2 cells with
stable Agpat2 knockdown and human wild-type or mutant AGPAT2
re-expression at day 0 and after 8 days of adipogenic differentiation. All
real time PCR data are shown +/SEM, n ¼ 3, * indicates difference of
p < 0.05, versus expression in cells re-expressing wild-type AGPAT2 at
the same time point determined using two-tailed paired Student’s T test.
All western blots and cell images are representative of at least three
independent experiments
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Synopsis
We have identified a novel mutation in the gene AGPAT2
causing generalised lipodystrophy and characterised this in
cultured models of adipocyte development which suggest
that the mutation results in a failure to express the protein
and a consequent lack of adipogenesis.
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